Since estrogen suppression, fulvestrant, and PRMT5i all exerted blockade of the G1-to-S transition independent of RB, we reasoned that anti-ER therapy plus a PRMT5i may serve as an effective combination strategy to treat ER+/RB-deficient breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.